Brean Capital reiterated their buy rating on shares of TG Therapeutics Inc. (NASDAQ:TGTX) in a report published on Thursday. Brean Capital currently has a $28.00 price target on the biopharmaceutical company’s stock.
A number of other research analysts have also recently issued reports on the stock. Roth Capital reaffirmed a buy rating and issued a $33.00 target price on shares of TG Therapeutics in a report on Wednesday, August 10th. FBR & Co reiterated a buy rating on shares of TG Therapeutics in a research report on Monday, September 19th. S&P Equity Research lowered their price target on shares of TG Therapeutics from $7.15 to $6.40 in a research report on Wednesday, August 24th. Finally, Zacks Investment Research lowered shares of TG Therapeutics from a strong-buy rating to a hold rating in a research report on Thursday, July 14th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of Buy and an average target price of $20.81.
TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative net margin of 40,142.11% and a negative return on equity of 58.77%.
A number of hedge funds have recently made changes to their positions in TGTX. BlackRock Advisors LLC raised its stake in shares of TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 2,296 shares during the period. Mariner Wealth Advisors LLC raised its stake in shares of TG Therapeutics by 1.4% in the first quarter. Mariner Wealth Advisors LLC now owns 18,286 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 255 shares during the period. SECOR Capital Advisors LP purchased a new stake in shares of TG Therapeutics during the second quarter worth about $187,000. Emerald Acquisition Ltd. purchased a new stake in shares of TG Therapeutics during the second quarter worth about $190,000. Finally, Rhumbline Advisers raised its stake in shares of TG Therapeutics by 9.0% in the second quarter. Rhumbline Advisers now owns 37,547 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 3,107 shares during the period. Hedge funds and other institutional investors own 54.66% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.